Detalhe da pesquisa
1.
Structure-based discovery of LpxC inhibitors.
Bioorg Med Chem Lett
; 27(8): 1670-1680, 2017 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28302397
2.
Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids.
Bioorg Med Chem Lett
; 22(19): 6248-51, 2012 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22951041
3.
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
Bioorg Med Chem Lett
; 21(12): 3743-8, 2011 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21561767
4.
Discovery of a Novel Cabazitaxel Nanoparticle-Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects Using a ß-Cyclodextrin-PEG Copolymer Based Delivery Platform.
J Med Chem
; 62(21): 9541-9559, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31593466
5.
SRC inhibitors in metastatic bone disease.
Clin Cancer Res
; 12(20 Pt 2): 6291s-6295s, 2006 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17062716
6.
Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior.
Cancer Res
; 65(4): 1335-42, 2005 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15735019
7.
Editor's Note: Identification of Src-Specific Phosphorylation Site on Focal Adhesion Kinase: Dissection of the Role of Src SH2 and Catalytic Functions and Their Consequences for Tumor Cell Behavior.
Cancer Res
; 82(13): 2500, 2022 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35788292
8.
Future anti-catabolic therapeutic targets in bone disease.
Ann N Y Acad Sci
; 1068: 447-57, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16831942
9.
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.
Mol Cancer Ther
; 4(12): 1900-11, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16373705
10.
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design.
ACS Med Chem Lett
; 7(4): 374-8, 2016 Apr 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27096044
11.
Discovery of Azaindole Ureas as a Novel Class of Bacterial Gyrase B Inhibitors.
J Med Chem
; 58(21): 8503-12, 2015 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26460684
12.
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.
ACS Med Chem Lett
; 6(10): 1080-5, 2015 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26487916
13.
Targeting protein kinases for bone disease: discovery and development of Src inhibitors.
Curr Pharm Des
; 8(23): 2049-75, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12171518
14.
Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Curr Opin Drug Discov Devel
; 6(5): 729-41, 2003 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-14579523
15.
SRC homology-2 inhibitors: peptidomimetic and nonpeptide.
Mini Rev Med Chem
; 2(5): 475-88, 2002 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-12370048
16.
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
J Med Chem
; 53(12): 4701-19, 2010 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-20513156
17.
Novel protein kinase inhibitors: SMART drug design technology.
Biotechniques
; Suppl: 2-10, 12-5, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12813899
18.
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Cancer Cell
; 16(5): 401-12, 2009 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-19878872
19.
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Proc Natl Acad Sci U S A
; 103(24): 9244-9, 2006 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-16754879
20.
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
Cancer Res
; 66(17): 8633-9, 2006 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16951177